skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Authors:
 [1];  [1];  [1];  [2];  [2];  [3];  [4];  [5];  [4];  [5];  [4];  [3];  [4];  [4];  [4];  [4]
  1. Veterans Affairs San Diego Healthcare System, San Diego CA USA, Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego CA USA
  2. Veterans Affairs San Diego Healthcare System, San Diego CA USA
  3. Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego CA USA
  4. Eli Lilly and Company, Indianapolis IN USA
  5. Eli Lilly and Company, Singapore Singapore
Publication Date:
Sponsoring Org.:
USDOE Office of Environmental Management (EM), Acquisition and Project Management
OSTI Identifier:
1401715
Resource Type:
Publisher's Accepted Manuscript
Journal Name:
Diabetes, Obesity and Metabolism
Additional Journal Information:
Journal Name: Diabetes, Obesity and Metabolism Journal Volume: 18 Journal Issue: supplement S2; Journal ID: ISSN 1462-8902
Publisher:
Wiley-Blackwell
Country of Publication:
Country unknown/Code not available
Language:
English

Citation Formats

Mudaliar, S., Henry, R. R., Ciaraldi, T. P., Armstrong, D. A., Burke, P. M., Pettus, J. H., Garhyan, P., Choi, S. L., Knadler, M. P., Lam, E. C. Q., Prince, M. J., Bose, N., Porksen, N. K., Sinha, V. P., Linnebjerg, H., and Jacober, S. J. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. Country unknown/Code not available: N. p., 2016. Web. doi:10.1111/dom.12753.
Mudaliar, S., Henry, R. R., Ciaraldi, T. P., Armstrong, D. A., Burke, P. M., Pettus, J. H., Garhyan, P., Choi, S. L., Knadler, M. P., Lam, E. C. Q., Prince, M. J., Bose, N., Porksen, N. K., Sinha, V. P., Linnebjerg, H., & Jacober, S. J. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. Country unknown/Code not available. doi:https://doi.org/10.1111/dom.12753
Mudaliar, S., Henry, R. R., Ciaraldi, T. P., Armstrong, D. A., Burke, P. M., Pettus, J. H., Garhyan, P., Choi, S. L., Knadler, M. P., Lam, E. C. Q., Prince, M. J., Bose, N., Porksen, N. K., Sinha, V. P., Linnebjerg, H., and Jacober, S. J. Mon . "Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes". Country unknown/Code not available. doi:https://doi.org/10.1111/dom.12753.
@article{osti_1401715,
title = {Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes},
author = {Mudaliar, S. and Henry, R. R. and Ciaraldi, T. P. and Armstrong, D. A. and Burke, P. M. and Pettus, J. H. and Garhyan, P. and Choi, S. L. and Knadler, M. P. and Lam, E. C. Q. and Prince, M. J. and Bose, N. and Porksen, N. K. and Sinha, V. P. and Linnebjerg, H. and Jacober, S. J.},
abstractNote = {},
doi = {10.1111/dom.12753},
journal = {Diabetes, Obesity and Metabolism},
number = supplement S2,
volume = 18,
place = {Country unknown/Code not available},
year = {2016},
month = {10}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
DOI: https://doi.org/10.1111/dom.12753

Citation Metrics:
Cited by: 6 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Insulin's direct effects on the liver dominate the control of hepatic glucose production
journal, January 2006

  • Edgerton, D. S.
  • Journal of Clinical Investigation, Vol. 116, Issue 2
  • DOI: 10.1172/JCI27073

Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes
journal, June 2015

  • Gregory, Justin M.; Kraft, Guillaume; Scott, Melanie F.
  • Diabetes, Vol. 64, Issue 10
  • DOI: 10.2337/db15-0071

Insulin Levels After Portal and Systemic Insulin Infusion Differ in a Dose-Dependent Fashion
journal, December 1998

  • De Vos, P.; De Haan, B.; Vegter, D.
  • Hormone and Metabolic Research, Vol. 30, Issue 12
  • DOI: 10.1055/s-2007-978966

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects: Journal of Clinical Pharmacology
journal, February 2014

  • Sinha, Vikram P.; Choi, Siak Leng; Soon, Danny Kwang Wei
  • The Journal of Clinical Pharmacology, Vol. 54, Issue 7
  • DOI: 10.1002/jcph.276

"Normal" Insulin Secretion: The Goal of Artificial Insulin Delivery Systems?
journal, March 1980


Pulsatile Insulin Secretion Dictates Systemic Insulin Delivery by Regulating Hepatic Insulin Extraction In Humans
journal, May 2005


Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM
journal, October 2013

  • Jacober, S. J.; Rosenstock, J.; Bergenstal, R. M.
  • Diabetes, Obesity and Metabolism, Vol. 16, Issue 4
  • DOI: 10.1111/dom.12223

In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog
journal, March 2016

  • Owens, R. A.; Hansen, R. J.; Kahl, S. D.
  • Journal of Pharmacology and Experimental Therapeutics, Vol. 357, Issue 3
  • DOI: 10.1124/jpet.115.231035

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
journal, November 2015

  • Buse, John B.; Rodbard, Helena W.; Trescoli Serrano, Carlos
  • Diabetes Care, Vol. 39, Issue 1
  • DOI: 10.2337/dc15-1531

A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial
journal, October 2016

  • Grunberger, G.; Chen, L.; Rodriguez, A.
  • Diabetes, Obesity and Metabolism, Vol. 18
  • DOI: 10.1111/dom.12743

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
journal, October 2013

  • Moore, M. C.; Smith, M. S.; Sinha, V. P.
  • Diabetes, Vol. 63, Issue 2
  • DOI: 10.2337/db13-0826

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
journal, September 2016

  • Ginsberg, Henry; Cariou, Bertrand; Orchard, Trevor
  • Diabetes, Obesity and Metabolism, Vol. 18, Issue 11
  • DOI: 10.1111/dom.12754

Hepatoselectivity and the evolution of insulin
journal, May 2013

  • Herring, R.; Jones, R. H.; Russell-Jones, D. L.
  • Diabetes, Obesity and Metabolism, Vol. 16, Issue 1
  • DOI: 10.1111/dom.12117

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
journal, August 2016

  • Davies, M. J.; Russell-Jones, D.; Selam, J. -L.
  • Diabetes, Obesity and Metabolism, Vol. 18, Issue 11
  • DOI: 10.1111/dom.12712